Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Integer Holdings ( (ITGR) ).
Integer Holdings Corporation reported an 8% increase in sales for the third quarter of 2025, with significant growth in cardio and vascular sales driven by new product introductions and acquisitions. Despite a decrease in GAAP operating income, the company achieved a 14% rise in non-GAAP adjusted operating income and a 25% increase in adjusted EPS. Integer anticipates challenges in 2026 but expects a return to above-market growth by 2027, supported by its robust product development pipeline.
The most recent analyst rating on (ITGR) stock is a Buy with a $133.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.
Spark’s Take on ITGR Stock
According to Spark, TipRanks’ AI Analyst, ITGR is a Outperform.
Integer Holdings’ overall stock score is driven by strong financial performance and positive earnings call results, highlighting robust sales and earnings growth. However, the high P/E ratio suggests potential overvaluation, and technical indicators point to possible short-term weakness. The absence of a dividend yield further impacts the valuation score.
To see Spark’s full report on ITGR stock, click here.
More about Integer Holdings
Integer Holdings Corporation operates in the medical device industry, focusing on the development and manufacturing of medical technologies. The company specializes in cardio and vascular products, cardiac rhythm management, neuromodulation, and other medical markets, with a strong emphasis on innovation and customer demand.
Average Trading Volume: 408,321
Technical Sentiment Signal: Buy
Current Market Cap: $3.78B
For a thorough assessment of ITGR stock, go to TipRanks’ Stock Analysis page.